Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Effect of android fat distribution on thrombin-activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.

Mendonça-Louzeiro MRMF, Andrade KC, Yela DA, Benetti-Pinto CL.

Int J Gynaecol Obstet. 2018 Oct;143(1):108-109. doi: 10.1002/ijgo.12571. Epub 2018 Jul 12. No abstract available.

PMID:
29931680
2.

Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.

de Mendonça-Louzeiro MR, Annichino-Bizzacchi JM, Benetti-Pinto CL.

Fertil Steril. 2015 Aug;104(2):467-73. doi: 10.1016/j.fertnstert.2015.05.013. Epub 2015 Jun 11.

PMID:
26051101
3.

Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.

Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A, Sahin HG.

Fertil Steril. 2010 Jul;94(2):666-72. doi: 10.1016/j.fertnstert.2009.03.037. Epub 2009 Apr 14.

PMID:
19368913
4.

Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.

Güldaş M, Altinkaya SÖ, Nergiz S, Demircan-Sezer S, Yüksel H.

Gynecol Endocrinol. 2015 Jul;31(7):536-9. doi: 10.3109/09513590.2015.1018161. Epub 2015 Jul 29.

PMID:
26220768
5.

Women with polycystic ovary syndrome have greater muscle strength irrespective of body composition.

Kogure GS, Silva RC, Picchi Ramos FK, Miranda-Furtado CL, Lara LA, Ferriani RA, Dos Reis RM.

Gynecol Endocrinol. 2015 Mar;31(3):237-42. doi: 10.3109/09513590.2014.982083. Epub 2014 Nov 28.

PMID:
25430509
6.

Comparison of regional fat mass measurement by whole body DXA scans and anthropometric measures to predict insulin resistance in women with polycystic ovary syndrome and controls.

Glintborg D, Petersen MH, Ravn P, Hermann AP, Andersen M.

Acta Obstet Gynecol Scand. 2016 Nov;95(11):1235-1243. doi: 10.1111/aogs.12964.

PMID:
27529295
7.

Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome.

Ezeh U, Pall M, Mathur R, Azziz R.

Hum Reprod. 2014 Jul;29(7):1508-17. Epub 2014 May 9.

8.
9.

No increased systemic fibrinolysis in women with heavy menstrual bleeding.

Wiewel-Verschueren S, Knol HM, Lisman T, Bogchelman DH, Kluin-Nelemans JC, van der Zee AG, Mulder AB, Meijer K.

J Thromb Haemost. 2014 Sep;12(9):1488-93. doi: 10.1111/jth.12645. Epub 2014 Jul 23.

10.
11.

Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index.

de Mendonça-Louzeiro MR, Annichino-Bizzacchi JM, Magna LA, Quaino SK, Benetti-Pinto CL.

Fertil Steril. 2013 May;99(6):1786-90. doi: 10.1016/j.fertnstert.2013.01.105. Epub 2013 Feb 15.

PMID:
23415973
12.

Thrombin activatable fibrinolysis inhibitor as a bleeding predictor in liver transplantation: a pilot observational study.

Nedel WL, Rodrigues Filho EM, Pasqualotto AC.

Rev Bras Ter Intensiva. 2016 Jun;28(2):161-6. doi: 10.5935/0103-507X.20160031. English, Portuguese.

13.

Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome.

Godoy-Matos AF, Vaisman F, Pedrosa AP, Farias ML, Mendonça LM, Pinheiro MF.

Gynecol Endocrinol. 2009 Dec;25(12):793-8. doi: 10.3109/09513590903015528.

PMID:
19905998
14.

Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome.

Bruns CM, Baum ST, Colman RJ, Dumesic DA, Eisner JR, Jensen MD, Whigham LD, Abbott DH.

Int J Obes (Lond). 2007 Oct;31(10):1579-85. Epub 2007 May 1.

15.

Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.

Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.

Gynecol Endocrinol. 2009 Feb;25(2):110-6. doi: 10.1080/09513590802549874.

PMID:
19253106
16.

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.

Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.

J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27.

17.

A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.

Zhou J, Kochan J, Yin O, Warren V, Zamora C, Atiee G, Pav J, Orihashi Y, Vashi V, Dishy V.

J Thromb Haemost. 2017 May;15(5):961-971. doi: 10.1111/jth.13658. Epub 2017 Mar 11.

PMID:
28211169
18.

Assessment of the body composition of patients with polycystic ovary syndrome using dual-energy X-ray absorptiometry.

Macruz CF, Lima SM, Salles JE, da Silva GM, Scalissi NM.

Int J Gynaecol Obstet. 2017 Mar;136(3):285-289. doi: 10.1002/ijgo.12066. Epub 2017 Jan 6.

PMID:
28099715
19.

Body fat distribution and its associated factors in Korean women with polycystic ovary syndrome.

Jin CH, Yuk JS, Choi KM, Yi KW, Kim T, Hur JY, Shin JH.

J Obstet Gynaecol Res. 2015 Oct;41(10):1577-83. doi: 10.1111/jog.12767. Epub 2015 Aug 9.

PMID:
26257142
20.

Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome.

Wehr E, Möller R, Horejsi R, Giuliani A, Kopera D, Schweighofer N, Groselj-Strele A, Pieber TR, Obermayer-Pietsch B.

Wien Klin Wochenschr. 2009;121(7-8):262-9. doi: 10.1007/s00508-009-1162-2.

PMID:
19562283

Supplemental Content

Support Center